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Abstract
Background and Aims: Current cardiovascular disease (CVD) prevention is based on diagnosis and treatment of specific
disease. Little is known for high risk people with CVD at the community level. In rural China, health records of all residents
were established after the recent health reforms. This study aims to describe the characters of the rural population with high
CVD risk regarding their clinical indicators, disease patterns, drug treatment and adherence.
Methods and Results: 17042 (87%) of all the 19500 rural residents in the two townships had valid health records in 2009.
We employed a validated tool, the Asian Equation, to screen 8182 (48%) resident health records of those aged between 40–
75 years in 2010. Those who were identified with a CVD risk of 20% or higher were selected for a face-to-face questionnaire
survey regarding their diagnosed disease and drug treatment. 453 individuals were identified as high risk of CVD, with an
average age of 53 years, 62% males, 50% smoking rate and average systolic blood pressure of 161 mmHg. 386 (85%)
participated in the survey, while 294 (76%) were diagnosed with and 88 (23%) were suspects of CVD, hypertension, diabetes
or hyperlipidaemia. 75 (19%) took drug regularly and 125 (32%) either stopped treatment or missed drugs. The most often
used drugs were calcium channel blockers (20%). Only 2% used aspirins and 0.8% used statins. The median costs of drugs
were 17 RMB (USD2.66) per month.
Conclusion: The majority of the high risk population in our setting of rural China had already been diagnosed with a CVD
related disease, but very few took any drugs, and less still took highly effective drugs to prevent CVD. A holistic strategy
focused on population with high risk CVD and based on the current China public health reform is suggested in the context
of primary care.
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Introduction
Cardiovascular disease (CVD) is the leading cause of death in
China, accounting for 38% of total mortality [1]. China’s rapid
economic development has resulted in an increase in non-
communicable chronic diseases. The lifestyle of Chinese popula-
tions has changed dramatically, mirroring that of more affluent
countries with sedentary lifestyles, higher consumption of meat
and changing diets, which are high in salt, sugar and fats. In 2006,
China was estimated to have 160 million people with hyperten-
sion, 160 million with hyperlipidaemia, 20 million with diabetes
and 200 million who were overweight [1]. The reported mortality
rates of stroke had increased at a faster rate in rural areas
compared to urban areas between 1990 and 2001, while the
reported stroke mortality rates fluctuated in both rural and urban
areas from 2001 to 2004 [2]. Compared with the Western
population, Chinese population has a higher proportion of
reported haemorrhagic stroke [3]. Some studies reported that
the variation of the proportions of haemorrhagic stroke was also
large between the north and south China [4]. Haemorrhagic
stroke incidence rates in rural China may be much higher than
reported rates due to the underreported mortality cases of
haemorrhagic stroke and the less use of key diagnostic tools such
as computed tomography (CT) and magnetic resonance imaging
(MRI) scanning in stroke patients [2,5]. It is predicted that annual
CVD events in China will increase by 23% from 2010 to 2030.
This will result in an additional 21 million CVD events and 7.7
million CVD deaths [6]. It is predicted that China will lose
US$558 million in national income as a result of CVD and
diabetes over the next 10 years [7].
The overall risk prediction strategy considers all risk factors in a
person and calculates the overall CVD risk to inform treatment
decisions. It is advocated that separate management guidelines for
hypertension and diabetes should be replaced by integrated CVD
risk management guidelines, because individuals with given blood
pressure may have a 20-fold variation in CVD risk due to other
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factors such as smoking, age, body mass index and diabetes status
[8]. The risk assessment tool needs to be revalidated in specific
populations, because systematic reviews found that some tools
under-predicted risk in high risk groups and over-predicted risks in
low risk groups among Chinese population [9].
In this study, we applied the Asian Equation to assess the
absolute CVD risk of a rural population in China. The Asian
Equation was derived based on population cohorts joined in the
Asia Pacific Cohort Studies Collaboration, i.e., a total of 172,077
individuals who were followed up for 4–20 years in Japan, Korea
and Singapore [10]. The equation had fewer variables for CVD
risk prediction compared with the Framingham one to fit for the
low information availability in developing countries. It calculates a
person’s percentage risk of having any CVD event in the next 8
years; based on his/her gender, age, systolic blood pressure, total
cholesterol and smoking status. The performance of the Asian
Equation has been validated using six Chinese cohorts of 25,682
individuals with up to 12 years follow-up in both urban and rural
China, and was compared with a recalibrated Framingham
Equation for Chinese population [10]. The outcome of interest
was any cardiovascular event, defined as cardiovascular death,
non-fatal myocardial infarction or non-fatal cerebrovascular
events. This showed a 11% and 10% overestimation of CVD
events in men and women compared with 276% and 102% of
overestimation in men and women by the recalibrated Framing-
ham equation [10]. Its discrimination ability is similar to other
CVD risk prediction equations [11,12]. Currently, the Asian
Equation is the best available tool that can effectively predict both
ischaemic and haemorrhagic CVD events in Chinese population,
while other tools can only predict ischaemic CVD events but not
haemorrhagic stroke [11,12].
Systematic reviews suggest that using two antihypertensive
drugs simultaneously will reduce the risk of stroke by 63% and
ischaemic disease by 46% [13], while statins will reduce the risk by
60% and 17% respectively [14]. The combined effects of three
antihypertensive drugs, plus a statin and aspirin would reduce by
more than 88% ischaemic heart disease events and by 80% stroke
events [15]. Furthermore folic acid reduces the risk of stroke by
18% [16] in hypertensive patients with high concentration of
hyperhomocysteinemia; and up to 75% of hypertensive patients
have high hyperhomocysteinemia [17,18]. Food in China is not
yet fortified with folic acid. Two recent trials of the fixed-dose
combination (known as polypill) successfully reduced systolic blood
pressure by 6–7 mmHg, which translates as around 60–75% CVD
risk reduction in the general population over 45 years old [19,20].
Therefore, we examined use of antihypertensive drugs, statin,
aspirin and folic acid among the high risk people with
cardiovascular disease in Chinese rural areas.
With the health reform launched in China, one strategy was to
improve public health service at the primary care level [21], and to
set up resident health records containing social and bio indicators
of all residents in the community. This enables the use of risk
assessment tools. In this study, we employed the Asian Equation to
identify population with high CVD risk from the health records of
two townships in rural Zhejiang China. The study aims to describe
the characters of the rural population with high CVD risk
regarding their blood pressures, lipid profile, disease patterns, drug
treatment and adherence. Specific objectives of the study are: (1) to
screen and identify people with high CVD risk using health
records of rural residents collected in routine primary care settings;
(2) to find out disease patters and risk factors for those people at
high CVD risk; and (3) to assess whether their diseases and risk
factors have been treated properly. The paper also discusses the
possibility of launching a CVD risk based treatment strategy in
rural China.
Methods
Setting
Zhejiang is located in the east of China, with a GDP per capita
of USD7690, 1.8 times of the national average. We selected two
townships with a population of 19,500 in central Zhejiang. The
two townships were of average economic development in
Zhejiang, and presented a typical rural community.
Data Collection
All rural residents in the study area have participated in the
New Cooperative Medical Scheme (NCMS), i.e., the rural health
insurance scheme in China. Free health checks are provided as a
benefit to enrolled residents annually and the results are stored in
health records. We employed all routine health checks collected
between July and December 2009 in the studied area. The Asian
Equation was applied to the database of resident health records in
the two rural townships for those between 40–75 years old. The
Asian Equation was validated for those below 75 years old [10],
while UK NICE guidelines suggest targeting CVD prevention for
people aged above 40 [22,23]. Those who were identified with a
CVD disease risk of 20% or higher were selected for a face to face
questionnaire survey regarding their diagnosed disease, current
treatment with drugs, adherence and costs of drugs, if any.
Diagnosis of CVD, hypertension, diabetes and hyperlipidaemia
were made according to China national guidelines [5] and
recorded in the resident health records. Variables regarding
diagnosis, gender, age, body mass index, blood pressures and total
cholesterol were extracted from the resident health records.
Smoking was defined as current smokers with at least one
cigarette a day regardless of the duration of smoking, which was in
line with the definitions of smoking rate in the Asian Equation
[10]. Family doctors of the township hospitals were trained and
collected the data in 2010. Ethics approval was obtained from the
Zhejiang University ethical committee. Written informed consent
forms were collected from all participants.
Analysis
Data was checked, coded and double entered into a database
using Epidata and then analyzed using SPSS 14.0 (Chicago, USA).
Descriptive analysis including independent t-test, chi-square test,
and non-parametric data comparison were used when appropri-
ate. P= 0.05 was quoted consistently as the statistical significance
level.
Results
In the studied area, 17,042 (87%) of all the 19,500 residents had
valid health records. The proportions of males were similar
between residents with health records and all the residents (50.6%
vs. 51.8%). Proportions of the age bands of 0–14, 15–59 and $60
were 14.0%, 71.9% and 14.1% in all the residents and 10.0%,
74.1% and 15.9% in residents with health records, respectively.
Although residents with health records were slightly older
compared with all the residents, the statistical difference may be
drawn due to the large numbers in each cell of the chi-square
table. Of the two townships, 8182 residents (48%) between 40 and
75 years old were assessed (Table 1). The Asian Equation
identified 453 residents having a CVD risk of 20% or higher in
the next 8 years, accounting for 5.5% of the residents between 40
to 75 years old, or 2.3% of the total population. The median risk of
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CVD in the high risk population was 26.4%, which was 7.3 times
the median risk of the low risk population and 6.9 times of the
general population. The average age of the high risk population
was 69 years old, significantly higher than that of the population
with CVD risk less than 20%. The high CVD risk population had
significantly more males than the low risk population. The
smoking rate of the population with high CVD risk was 1.8 times
that of the low risk population. Compared with the low risk
population, the high CVD risk population had significantly higher
average systolic blood pressure, diastolic blood pressure and total
cholesterol level. Of people at high CVD risk, 21.9% had fasting
blood glucose over 6.1 mmol/L, indicating impaired fasting
glycaedemia or diabetes. This proportion was significantly lower
among the low risk population. These differences between high
and low risk populations for BP and cholesterol remained when
analysed separately for men and for women.
Of the 453 with high CVD risk, 386 (85%) participated in the
survey, 67 (15%) were not included because they were not reached
after three attempts over one week. The median CVD risk of the
67 individuals who did not participate in the study was 26.3%,
similar to that of the 386 who participated in the study. 62% of the
participants were males, with an average age of 70 years. 294
(76%) had confirmed diagnosis of CVD or related disease: 37
(10%) had coronary heart disease, ischaemic or haemorrhagic
cerebro-vascular disease, or heart attack, 269 (70%) had hyper-
tension, 38 (10%) had diabetes, and 24 (6%) had hyperlipidaemia
(Table 2). There were 92 (24%) subjects who had not been
diagnosed any diseases. However, when their clinical details were
compared with the national diagnostic guidelines [5,24], 70 (76%)
were suspects of hypertension, diabetes or hyperlipidaemia; and
more females than males were likely to be suspects of CVD related
disease. In total, 364 (94%) of individuals with risk of CVD 20% or
higher, already had a diagnosed disease or were found to be
suspects of having a CVD related disease when compared their
recorded clinical information with the criteria in the national
guidelines.
Of the 294 high risk individuals with diagnosed CVD or related
disease, 200 (68%) had ever taken drugs in the last two years. All
the 92 high risk individuals not being diagnosed of any disease did
not take drugs. At the time of survey, 101 were currently taking
drugs, while 99 has stopped taking any drugs (Figure 1). Of the 200
patients who had ever taken drugs, 75 (38%) reported never
missing their drugs, 88 (44%) reported missing at least one dose
per week, while the remaining 37 (19%) reported having occasions
of stopping treatment for at least a month. 165 (83%) reported
following physician’s prescribed doses, while 28 (14%) reported
taking less than the prescribed doses and 7 (14%) reported taking
more than the prescribed doses. There were no significant
difference between men and women regarding drug adherence.
Of the 200 who have taken drugs in the last two years, 76 (38%)
reported using of calcium channel blocker drugs, 43 (22%) used
angiotensin converting enzyme inhibitors (ACEi), 34 (17%) used
thiazide diuretics and 6 (3%) used beta blockers. Only 8 (4%) used
aspirin, 3 (1.5%) used statin and 1 (0.5%) used folic acid. In
general 137 (69%) used any of the above drugs, while only 27
(13.5%) used a combination of any two or more of the above
drugs. 69 (35%) reported ever used compounds containing
modern (e.g. reserpine) and traditional Chinese medicines, such
as kendir leaves and red sage root. More women (77%) than men
(60%) used any of the above drugs; otherwise, there was no
significant difference between genders regarding use of any
particular type of drugs. The majority of respondents purchased
their drugs from pharmacies, while 27% got prescriptions and
purchased from township and county hospitals, and 24% had
drugs purchased both from hospitals and pharmacies. The median
cost of drugs was RMB 17 (USD2.66) per month. Women spent
significantly more on CVD related drugs than men (RMB 20 vs.
12) (Table 3).
Discussion
The study used a validated risk assessment tool to screen a rural
population in China for having high risk of CVD. 5.5% of
Table 1. Cardiovascular (CVD) risks factors of the 8182 rural residents aged 40 to 75 years old in Zhejiang, China.
Population with high risk of CVD Population with low risk of CVD General population
Male Female Sub-total Male Female Sub-total Male Female Sub-total
Number 280 (62)a 173 (38) 453 3562(46) 4167 (54) 7729 3842 (47) 4340 (53) 8182
Age 68 70 69b 53 53 53 54 54 54
Systolic blood pressure
(mmHg)
155.1 170.0 160.8c 120.6 122.4 121.6 123.0 124.2 123.7
Diastolic blood pressure
(mmHg)
86.5 90.5 88.1d 77.4 76.4 76.9 77.9 76.9 77.4
Fasting blood glucose
(FBG) (mmol/L)
5.6 5.8 5.7e 5.5 5.6 5.6 5.5 5.6 5.6
Number and proportion
of people with
FBG§6.1 mmol/L
52 (18.6) 47 (27.2) 99 (21.9)f 620 (17.4) 663 (15.9) 1283 (16.6) 672 (17.5) 710 (16.4) 1382 (16.9)
Total cholesterol level
(mmol/L)
4.8 4.9 4.8g 4.5 4.6 4.6 4.5 4.6 4.6
BMI 22.0 22.8 22.3 22.4 22.7 22.5 22.4 22.7 22.5
Smoking rate (%) 207 (73.9) 9 (5.2) 216 (47.7)h 2002 (56.1) 79 (1.9) 2079 (26.9) 2209 (57.4) 88 (2.0) 2297 (28.1)
Median of CVD risk (%) 26.5 25.9 26.4i 4.3 2.9 3.6 4.8 3.1 3.8
Significantly higher than the population with low risk of CVD: a(x2 = 42.478, P,0.001), b(t = 38.733, P,0.001), c(t = 44.737, P,0.001), d(t = 21.040, P,0.001), e(t = 2.800,
P = 0.005), f(x2 = 8.416, P = 0.004), g(t = 4.730, P,0.001), h(x2 =291.588, P,0.001), i(Z =235.261, P,0.001).
doi:10.1371/journal.pone.0054169.t001
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residents aged between 40 to 75 years (2.3% of the total
population) were identified as having a CVD risk of 20% or
more over within 8 years. The record review and interview found
that the majority (76%) of those with a CVD risk of 20% or higher
had been diagnosed: over 70% had hypertension, 10% had
diabetes and 10% had a cardiovascular disease such as angina. Of
Table 2. Diagnosis of people with high risk of cardiovascular disease (CVD) in a rural primary care setting in Zhejiang, China.
Male Female Total
Participants 240(62.2) 146(37.8) 386
Age 69 71 70
Those with a diagnosed disease: 166(69.2) 128(87.7)a 294(76.2)
Any CVD(%) 19(7.9) 18(12.3) 37(9.6)
Hypertension(%) 145(60.4) 124(84.9)b 269(69.7)
Diabetes(%) 26(10.8) 12(5.0) 38(9.8)
Hyperlipidaemia(%) 12(5.0) 12(8.2) 24(6.2)
Those without a diagnosed disease: 74(30.8) 18(12.3) 92(23.8)
Suspects of hypertension, diabetes or
hyperlipidaemia (%)
52(70.3) 18(100.0)c 70(76.1)
Suspects of hypertension 48 18 66
Suspects of diabetes 9 0 9
Suspects of dislipidaemia 1 0 1
With or being suspects of a diagnosed CVD related
disease (%)
218(90.8) 146(100.0)d 364(94.3)
Significantly higher than males: a(x2 =217.123, P,0.001), b(x2 =225.827, P,0.001), c(Fisher’s exact test, P = 0.005), d(x2 = 14.192, P,0.001).
CVD include coronary heart disease, heart attack, and ischaemic or haemorrhagic cerebro-vascular disease.
doi:10.1371/journal.pone.0054169.t002
Figure 1. Number of people with high risk of cardiovascular disease (CVD) identified and their characteristics on diagnosis and
drug taking in a rural primary care setting in Zhejiang, China.
doi:10.1371/journal.pone.0054169.g001
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those of high CVD risk not being diagnosed with a disease, the
majority had elevated blood pressures, fasting blood glucose or
lipid profile as compared to the national diagnostic guidelines [24].
Thus, they may be likely to be diagnosed as hypertension, diabetes
(including pre-diabetes) or hyperlipidaemia after further clinical
investigation. In the end, it is likely that over 94% of the high risk
population should be diagnosed with CVD or related diseases.
Our findings suggest that this record review and CVD risk
assessment strategy is useful in the detection of undiagnosed
patients. Indeed, the majority of our undiagnosed high risk
population was hypertensive or diabetic patients. The majority of
residents who had hypertension or diabetes in this study in rural
China were not aware of their diseases and/or not getting proper
treatment. A national survey showed a 8.2% diabetes prevalence
in rural areas in 2008; however, the rate of diagnosed diabetes was
only 2.7% [25]. The 2002 national hypertension survey showed
that 23% patients with hypertension were aware of it, 17% were
on treatment, and 4% had their blood pressure under control [26].
Using this risk approach has cost-effective implication on the
detection and treatment of CVD patients as well. A previous
modeling study showed that applying risk assessment tools would
result in treating the same number of patients as in the usual care
as treating only patients identified with CVD related diseases.
However, the risk screening approach, prioritising identification
and treatment of those with high CVD risk, should prevent more
CVD events and be more cost effective according to estimates in
the modeling study [27].
In this study, we examined the use of highly effective drugs to
prevent CVD events based on suggestions from systematic reviews
and trials. It was found very few (26%) of the rural residents with
high risk CVD were taking any drugs. A survey over 628
communities around the world found that less than one quarter of
CVD patients ever took these preventative drugs, while over half
of patients in developing countries did not use drugs at all [28].
The WHO PREMISE study reported over 70% of CVD patients
in developing countries received aspirin, and around 20–40%
received anti-hypertensive drugs and/or statins [29]. The WHO
study was largely based on patients from teaching hospitals, thus
resulting in a higher rates of drug intake compared with our study
which was community based.
The reasons of low use of the highly effective drugs need further
investigation, but are likely to include the limited knowledge of the
doctors, belief in traditional therapies, non use of a CVD risk
approach, and the cost of preventive drugs. However, these drugs
are widely available in rural China at relatively affordable costs.
Suppose that one takes the composition of nefidipine 30 mg,
hydrochlorothiazide 50 mg, simvastatin 40 mg, aspirin 75 mg and
folic acid 5 mg per day from the generic drugs, the total costs of
drugs per month is RMB111 (USD17.3) in rural Zhejiang. The
majority of the costs are from simvastatin, a statin. Without statin,
the combination of two antihypertensives, aspirin and folate only
costs as low as RMB6 (nearly US$1) per month. In addition, the
rural health insurance in China covers 30% of drugs purchased
from township hospitals. Paying the combination with statin may
not be affordable, because the cost is much higher than the current
RMB17 (USD6.3) per month found in our study, but paying a
combination without statin should not be a problem. Another
survey in northern China found hypertensive patients over-
estimated the effect of drug treatment, and were willing to pay
RMB 42 (USD6.6) per month for drug treatment if being
informed having a CVD risk of 35% in 5 years [30]. Another
possible reason is low awareness of the need of lifelong use of the
preventative drugs by doctors in rural practice, so the highly
effective drugs are simply not prescribed. For those taking drugs,
44% of participants in this study reported missing at least one dose
per week, while 19% reported having occasions of stopping
treatment for at least a month. Our findings suggest that
adherence to drugs could be a challenge in the CVD prevention
and treatment, echoing the study elsewhere [26,28]. Adherence
support strategies can be learned from tuberculosis control using
treatment supporters and reminders [31,32], though CVD is much
challenging because it needs life-long treatment.
The current health reform in China makes a CVD risk
reduction strategy feasible. The resident health records can
provide the basis to apply risk assessment and identify those with
high risk of CVD. Primary care facilities, including township
hospitals, village clinics and community health centres, are
strengthened with recent government policy investment in public
health activities. Chronic disease control has become a responsi-
bility of doctors and nurses at the primary care facilities. Zhejiang
provincial government has designated outpatient doctors in
township hospitals as ‘‘family doctors’’. One family doctor is
responsible for acute and preventative care, including chronic
disease control, for an average population of 1500. Currently in
China CVD risk reduction is not generally practiced [7]. Based on
this, we would suggest a holistic CVD risk reduction approach,
which should include screening patients/records, the use of highly
effective drugs, adherence support and healthy lifestyle support.
This package can be designed to be implemented by primary care
health workers in rural China [33].
Table 3. Drug use of the 200 rural residents with high risk of
cardiovascular disease (CVD) who were treated in a rural
primary care setting in Zhejiang China.
Males Females Total
Number 100 100 200
Drugs:
Calcium channel blockers
(%)
33(33.0) 43(43.0) 76(38.0)
Angiotensin converting
enzyme inhibitors (%)
17(17.0) 26(26.0) 43(21.5)
Thiazide diuretics (%) 14(14.0) 20(20.0) 34(17.0)
Beta channel blockers (%) 3(3.0) 3(3.0) 6(3.0)
Statins (%) 1(1.0) 2(2.0) 3(1.5)
Aspirin (%) 5(5.0) 3(3.0) 8(4.0)
Folic acid (%) 0 1(1.0) 1(0.5)
Use any of the above drugs
(%)
60(60.0) 77(77.0)a 137(68.5)
Use more than 1 of the
above drugs (%)
13(13.0) 14(14.0) 27(13.5)
Use of compound tablets
with traditional
Chinese Medicine (%)
31(31.0) 38(38.0) 69(34.5)
Resources of drugs:
Hospitals (%) 25(25.0) 28(28.0) 53(26.5)
Pharmacies (%) 53(53.0) 47(47.0) 100(50.0)
Both (%) 22(22.0) 25(25.0) 47(23.5)
Median costs of drugs per
month (RMB)
12 20b 17
The proportion/average of females are significantly higher than that of males:
a(x2 =26.697, P = 0.010), b(Z =22.389, P = 0.017).
doi:10.1371/journal.pone.0054169.t003
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The study has several limitations. First, the Asian Equation
estimates CVD events in 8 years while most other predictive
equations estimate for 10 years. Using a similar cut-off of 20% as
high CVD risk, the number of high risk people with CVD
identified by the Asian Equation may be lower than that identified
using other equations. However, the Asian equation has better
predictive value on both ischaemic and hamoerrhagic CVD events
compared with other equations in Chinese population. Second,
samples are taken from two townships in rural Zhejiang, thus, the
results cannot be extrapolated further. Third, information of the
resident health records were collected by doctors and nurses from
township hospitals. The accuracy may not be complete; however,
all doctors and nurses involved in building up the health record
were trained based on a provincial guideline, and all diagnosis of
CVD, hypertension, diabetes and hyperlipedaemia were checked
against their previous medical records. Fourth, a further caution in
interpretation is that 67 (15%) of the high risk population did not
participate in the survey, though their CVD risk was not different
from those who participated in the survey. Furthermore we did not
collect information in the survey regarding daily salt intake,
exercise or any healthy lifestyle advice given by their doctors or
nurses.
Conclusion
By examining the current situation of rural population with high
risk of CVD in China, the study found that the majority of the
high risk population had already been diagnosed with a CVD
related disease. However, only a quarter of these were currently
taking any drugs, and less still took highly effective drugs to
prevent CVD. We suggest a community-based CVD risk
reduction approach, designed to be implementable within the
current China public health and rural health insurance reforms, in
so doing improve care and reduce CVD events at the primary care
level.
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